Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

More information: Aleksandra E. Kamizela et al, Timing and trajectory of BCR::ABL1-driven chronic myeloid leukemia, Nature (2025). DOI: 10.1038/s41586-025-08817-2 Provided by Wellcome Trust Sanger ...

Leukemia Service, at Memorial Sloan Kettering Cancer Center, discusses the current understanding of TKI discontinuation and treatment-free remission in CML. Visit us on Facebook. Opens in a new ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine ...

For clinicians, it is bewildering when one patient with CBF leukemia is cured, and the next patient with an identical karyotype relapses ... AML: Acute myeloid leukemia; APL: Acute promyelocytic ...

Exposures to moderate-to-high doses of ionizing radiation have been associated with an increased risk of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and acute lymphoblastic ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in life and how fast it grows. Researchers reveal explosive growth rates of ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine ...

BCR::ABL1 Deep Molecular Response Quantification and Transcript Type Identification in Chronic Myeloid Leukemia Using a US Food and Drug Administration–Approved Droplet-Based Digital PCR Assay ...